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Abstract
Excess formation of nitric oxide (NO) has been invoked in the development of osteoarthritis and blamed for triggering chondrocyte apoptosis 
and matrix destruction. Much of the evidence for a deleterious role of NO in disease progression has been obtained indirectly and inferred 
from the measurement of nitrite/nitrate and nitrotyrosine concentrations as well as iNOS expression in biopsy specimen, cartilage explants 
and cytokine-stimulated cells in culture. While these results clearly indicate an involvement of NO and suggest additional contributions 
from oxidative stress-related components they do not necessarily establish a cause/effect relationship. Many NO metabolites are not mere 
dosimeters of local NO production but elicit potent down-stream effects in their own right. Moreover, oxygen tension and other experimental 
conditions typical of many in vitro studies would seem to be at odds with the particular situation in the joint. Recent insight into the chemical 
biology of NO, in particular with regard to cellular redox-regulation, mitochondrial signaling and nitration reactions, attest to a much richer 
network of chemical transformations and interactions with biological targets than hitherto assumed. In conjunction with the emerging biology 
of nitrite and nitrate this information challenges the validity of the long-held view that “too much NO” is contributing to disease progression. 
Instead, it suggests that part of the problem is a shift from NO to superoxide-dominated chemistries triggering changes in thiol-dependent 
redox signaling, hypoxia-induced gene expression and mitochondrial function. This essay aims to provide a glimpse into research areas that 
may hold promise for future investigations into the underlying causes of osteoarthritis.
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Introduction and scope of the problem
Osteoarthritis (OA), the most common form of joint disease, 
is a major cause of discomfort and disability in the elderly 
population. It affects >2 million people in the UK, >20 mil-
lion people in the United States and accounts for ~25% 
of all visits to primary care physicians in these countries. 
While the cause of the disease remains unknown, systemic 
and local mechanical factors seem to be involved with age, 
gender, heredity and life-style related factors such as body 
weight and physical activity all affecting disease risk one 
way or another. With obesity and sedentary life-styles on 
the rise the problem is expected to increase and become an 
even more signiﬁcant public health issue in the near future. 
Destruction and loss of articular cartilage is a central fea-
ture of OA and chronic pain its cardinal symptom, compro-
mising mobility and quality of life of those affected. 
No curative therapies are available for OA, limiting cur-
rent treatment goals to the management of symptoms and 
disease progression. OA alone accounts for roughly half 
of all non-steroidal anti-inﬂammatory drug prescriptions; 
besides analgesics other treatment options include intraar-
ticular glucocorticoid and hyaluronic acid injections and, 
in severe cases, joint replacement surgery. It has become 
increasingly clear in recent years that multiple cell types 
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and tissues that contribute to joint structure and function 
contribute to the disease and that an inﬂammatory compo-
nent is involved in its progression.1 Pro-inﬂammatory cyto-
kines play a central role in the formation of reactive oxygen 
species (ROS) and nitric oxide (NO), and both have been 
hypothesized to contribute to the development of OA.
The focus of the current paper is on NO and its relationship 
to OA; it does neither attempt to provide a general overview 
about the chemistry and enzymology of NO nor summarize 
the wealth of information available on its generation in OA. 
For this purpose the reader is referred to a number of excel-
lent reviews2–6 and comprehensive monographs.7,8 Instead, 
some aspects of NO biology that recently emerged in other 
research areas but do not seem to have been discussed 
much in the OA community will be highlighted in the hope of 
providing new “food for thought” and inform future research 
efforts on the role of NO in OA.
Nitric oxide – a jack-of-all-trades in cell 
regulation
NO is a pleiotropic signaling and effector molecule that 
has garnered a great deal of attention by both the basic 
and clinical research community. More than 80,000 papers 
related to the biochemistry as well as the cellular and 
molecular biology of NO have been published since its bio-
logical signiﬁcance was discovered, rather serendipitously, 
as “endothelium-derived relaxing factor (EDRF)” in isolated 
blood vessels about a quarter of a century ago.9 Within 
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a relatively short period of time EDRF was identiﬁed as 
NO10,11 and its enzymatic production from the amino acid, 
L-arginine shown to be a mammalian process. NO is pro-
duced by three distinct isoforms of the NO-synthase (NOS) 
enzyme family and their genes were mapped to three differ-
ent chromosomes of the human genome. These discover-
ies triggered a ﬂurry of research worldwide and it was soon 
established that NOS enzymes are not only constitutively 
expressed in discrete compartments of virtually every cell 
investigated but that the expression of one particular induc-
ible isoform increases dramatically during inﬂammation.a
NO emerged as a key regulator of blood vessel tone in the 
cardiovascular system, as a neurotransmitter in the central 
and peripheral nervous system, as a modulator of immune 
responses and as a cytotoxic effector molecule involved in 
host defense mechanisms.12
Within a couple of years NO had metamorphosed from 
an environmental pollutant and poisonous gas associated 
with ‘chemical smog’ to an endogenous master regulator of 
cell function.13 In recognition of its growing signiﬁcance NO 
was selected “Molecule of the Year” in 1992 by the journal 
Science, formed the basis for the 1996 Albert Lasker Basic 
Medical Research Award and led to the award of the 1998 
Nobel Prize for Physiology or Medicine for the discovery of 
NO “as a signaling molecule in the cardiovascular system”. 
How exactly does NO signal?
NO was long considered a highly diffusible ‘gas’ that freely 
moves about, crosses cell membranes with ease and can 
travel tens or hundreds of microns away from its site of pro-
duction.14 More recent concepts have raised doubt about 
this concept and suggested a very different picture where 
NO actions are much more localized and highly inﬂuenced 
by the local microenvironment. Early studies with NO and 
NO donors suggested that the binding of NO to the heme 
moiety of soluble guanylyl cyclase, an interaction that 
results in nitrosyl-heme formation and enzyme stimula-
tion with increased production of cyclic guanosine mono-
phosphate (cGMP), is the major if not sole pathway of NO 
signaling.15 The second messenger cGMP interacts with 
speciﬁc binding sites on target proteins (including protein 
kinases, phosphodiesterases, and cyclic nucleotide-gated 
ion channels) to elicit its downstream effects. Other exam-
ples of NO binding to heme proteins include interactions 
with cytochrome P-450 enzymes and cytochrome c oxidase 
(complex IV of the mitochondrial respiratory chain), leading 
to inhibition of enzyme activity. These NO effects have the 
potential to affect drug metabolism and modulate cellular 
energetics and are cGMP-independent.
Later studies conﬁrmed the existence of numerous other 
non-cGMP mediated effects in which NO either leads to 
post-translational modiﬁcations at sites other than hemes 
or contributes to the oxidation of biomolecules. The best 
characterized example of the former is represented by the 
S-nitros(yl)ation of low-molecular-weight thiols (e.g., cys-
teine and glutathione) and sulfhydryl groups of proteins. 
S-nitros(yl)ation has been shown to affect the activity of 
enzymes and transcription factors and coined the “proto-
typic redox-based signaling pathway”.16 Protein glutathiola-
tion, i.e. the addition of glutathione to a sulfhydryl group to 
form a mixed disulﬁde, represents an alternative pathway 
of redox-regulation by NO.17 In the majority of cases either 
type of reaction requires NO to be converted into secondary 
reaction products before it can interact with the sulfhydryl 
group.
An early recognition of the speed with which NO reacts 
with superoxide (O2•–) has lead to the appreciation that the 
formation of peroxynitrite (ONOO–) is intricately linked to 
NO biology. In the black-and-white images of the not-so-
distant past NO was viewed as “good”, superoxide as “bad” 
and peroxynitrite, a potent pro-oxidant with cell damaging 
effects, as “ugly”18 (Figure 1). However, peroxynitrite is more 
versatile than originally presumed, and its formation can give 
rise to oxidation and nitration reactions. Protein nitration has 
received the most attention, in part due to the ease with 
which nitrotyrosine (NO2Tyr) can be detected by immuno-
staining. The latter advanced to become a universal hall-
mark of inﬂammation and is frequently interpreted as “the 
footprint of peroxynitrite chemistry” as much as nitrite, nitrate 
and NO2Tyr are used as biomarkers of NO formation. As 
discussed later, there are biological targets other than tyro-
sine residues that become nitrated, including tryptophan,19
catecholamines, lipids, sugars20 and even cGMP itself.21,22
More importantly, the majority of NO2Tyr may be derived 
from sources other than peroxynitrite which will be further 
discussed. Nevertheless, the original notion that NO2Tyr 
originates from iNOS-derived peroxynitrite production stuck 
and NO2Tyr somehow managed to become synonymous 
with “too much NO”. The origin of this claim remains elu-
sive, but is presumably based on the assumption that iNOS 
always produces much more NO than the constitutive NOS 
isoforms (in fact, this has more to do with the shear amount 
of inducible protein expressed under inﬂammatory condi-
tions than its speciﬁc activity) and that high rates of NO pro-
duction can lead to DNA damage.23
A quarter of a century after the discovery of EDRF and 
>80,000 publications later, the interactions of NO with their 
biological targets remain incompletely understood. How 
NO makes it through the sea of antioxidants and other free 
radicals within the cell to reach its biological targets is just 
one of several aspects that remain unanswered. Although 
great strides have been made in unraveling a surprisingly 
rich chemistry of NO in biological environments, implicating 
transport and storage forms of NO that have the potential 
to enhance its radius and mode of action, the study of NO 
biology remains a challenging area of research. Analytical 
problems are just one of several areas of concern. Casual 
yet inappropriate oversimpliﬁcation of the biological chem-
istry of NO has led to an unfortunate level of confusion sur-
rounding the state-of-the-art. This seems to be particularly 
true for the area of translational research, and the fact that 
clinicians rarely become enthused about papers abound-
ing with chemical formulas and reaction pathways has not 
helped the case. 
Why is NO involved in the regulation of so many 
different functions?
NO formation and inﬂammation may have evolved as the 
ﬁrst-line defense mechanisms of the innate immune system 
to combat microbial infections.24 A question that has puz-
aThe different NOS isoforms were originally named after the 
cell/tissue type in which they were ﬁrst discovered, later renamed 
according to the order of their cloning, as eNOS (endothelial; 
NOS-3), nNOS (neuronal; NOS-1) and iNOS (inﬂammatory or 
LPS/cytokine-inducible; NOS-2).3 Adding to the confusion, we now 
know that the expression of the two “constitutive” enzymes, eNOS 
and nNOS can also be induced and that the “inducible” isoform is 
constitutively expressed in some tissues even in the absence of 
inﬂammation. 
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zled the research community for some time is how such a 
seemingly simple molecule as NO can fulﬁll so many dif-
ferent cell regulatory functions from bacteria to man and 
across the plant to the animal kingdom. More than a decade 
ago, Feelisch and Martin hypothesized that this may be so 
because the production of NO and its interaction with bio-
logical targets was one of the ﬁrst and most primitive of 
signaling systems that has survived to current use in more 
complex organisms because it provided, at a crucial phase 
of the development of life on earth, an evolutionary advan-
tage.25 If this is true, it would explain also why NO tends 
to interfere with signaling at multiple levels – from gene 
expression over modulation of enzyme activities by direct 
binding and post-translational protein modiﬁcation to anti-
oxidative effects and redox regulation of cellular function. 
Curiously, one of the biggest problems we faced during the 
writing of this hypothesis article then was to ﬁnd an expla-
nation for the transition from a relatively simple pathway of 
NO generation (e.g., denitriﬁcation) to the current pathway 
of NO formation via NOS. Clearly, the oxidation of L-argi-
nine with its sophisticated substrate transporter and cofac-
tor requirements looks way too complicated to have evolved 
from scratch. Much to our surprise, a decade later research 
suggested there was no need to look for an explanation as 
both pathways appear to happily coexist still in contempo-
rary mammalian cells.26
It is now known that NO can be produced not only from 
L-arginine by NOS, but also via reduction of nitrite and, 
due to reduction by the commensal bacterial ﬂora in our 
mouth and gut, even nitrate.27 The latter is likely a vestige 
of the evolutionary older pathway of NO production with 
contributions from multiple enzyme systems and subcellu-
lar compartments. Both pathways appear to regulate the 
expression, function and activity of proteins in similar ways, 
except that NO formation from L-arginine requires the pres-
ence of oxygen whereas that from nitrite is inhibited by its 
presence. While nitrite has been demonstrated to protect 
tissues against ischemia/reperfusion-related damage in 
several organs,27 it is not yet clear what role, if any, physi-
ological levels of nitrite, might play. Given the inverse 
dependence on oxygen, nitrite reduction to NO may serve 
to prevent a drop in NO concentration when oxygen levels 
fall below a critical threshold and NO production from NOS 
becomes insufﬁcient. 
Nitrite and nitrate – not just markers of NO
Nitrite and nitrate have long been considered biologically 
inert and traditionally been used as markers of NO forma-
tion. In inﬂammation, increased levels are observed due 
to NOS upregulation and increased NO production. How-
ever, as discussed above, it is clear that these simple oxy-
anions of nitrogen are not merely decomposition products 
of NO but have signiﬁcant biological effects in their own 
right. Whatever function nitrite may have in physiology and 
inﬂammation, hypoxic NO formation from nitrite is likely to 
be of particular relevance to OA because i) oxygen avail-
ability in the joint is rather low compared to other tissues; 
ii) its concentration is further reduced in inﬂammation; 
and iii) physiological oxygen supply of joint constituents is 
intermittent, reminiscent of recurring ischemia and reper-
fusion28 – conditions under which nitrite has been shown 
to exert protective effects. In addition to being reduced in 
hypoxia, nitrite was found to undergo rapid conversion to 
an array of metabolites (including S-nitrosothiols and NO-
heme species) indistinguishable from those produced by 
NO under aerobic conditions.26 Thus, nitrite and nitrate can 
no longer be regarded as simple dosimeters of enzymatic 
NO formation from NOS alone, but have to be considered 
precursors of NO production in tissues with limited oxygen 
availability. 
In addition to the nitrite/nitrate originating from endog-
enous NOS activity, the nutritional intake of nitrate (largely 
in the form of vegetables) may play an important disease 
modulatory role. Attempts to inﬂuence the course of arthritis 
by dietary means are not new, but little systematic research 
has been undertaken. In contrast, large well-controlled 
studies have demonstrated beneﬁcial effects of a diet rich in 
fruits and green leafy vegetables (e.g., Mediterranean diet) 
in chronic degenerative diseases, and nitrate has recently 
been proposed to account for part of this protective effect.29
Whether a similar degree of protection by dietary modulation 
of nitrate intake can be achieved in OA is unknown. Similarly 
Stimulation
of NOS Activity
NO2-
12
2
Enhanced
ROS Formation
³2[LGDWLYH6WUHVV´
2122
HbO2 UHGEORRGFHOOV
O2 (autoxida
tion
NO3-
127\Utyrosine nitration
SOD %LRPDUNHUVRI
123URGXFWLRQLQ
+HDOWK	'LVHDVH
H2O2
catalase
H2O + ½ O2
Oxidant
Signaling
Fig. 1. NO Metabolism as Conceptualized a Decade Ago – The Good (NO), the Bad (O2–), and the Ugly (ONOO–). Abbr.: H2O2 = hydrogen 
peroxide, HbO2 = oxyhemoglobin, NO = nitric oxide, NO2Tyr = nitrotyrosine, NO2– = nitrite, NO3– = nitrate, NOS = nitric oxide synthase, 
O2– = superoxide, ONOO– = peroxynitrite, ROS = reactive oxygen species, SOD = superoxide dismutase.
S6 M. Feelisch: Nitric oxide in osteoarthritis
unclear is which of the functional joint components would 
be most effective in generating NO from nitrite and which 
ones are likely targets of the NO produced. Since cartilage 
is an avascular tissue it would seem to be difﬁcult supplying 
NOS with all its necessary cofactors for prolonged periods 
of time. Although it has been demonstrated that cartilage 
explants can generate NO for days after removal from the 
joint30 the source of this NO remains unclear. Besides from 
NOS, it may originate from the decomposition of preformed 
NO storage forms or reduction of nitrite. 
NO is involved in the progression of 
osteoarthritis – fact or fiction?
The versatility of NO’s biological actions, in particular its 
ability to present as a physiological regulator of cellular pro-
cesses and as a cytotoxic molecule that kills bacteria and 
cancerous cells has puzzled researchers for years. We have 
become accustomed to phrases like “yin and yang”, “friend 
or foe”, “janus-faced” and “double-edged sword” in the con-
text of NO biology and medicine, and the “NO paradox” has 
become commonplace in discussions about inﬂammatory 
processes and degenerative diseases, regardless of disci-
pline. While knowing you are not alone can provide comfort, 
it does not really help in science – all it tells us is that we do 
not yet understand how NO works. 
There is no shortage of reports documenting cytotoxic 
and matrix destructive effects of NO in the OA literature4
and countless papers reiterate the importance of NO in OA 
disease progression. This is probably due to the fact that 
the original discovery of elevated nitrite concentrations in 
synovial ﬂuid and serum of patients suffering from rheu-
matic diseases,31 later conﬁrmed by other groups,32,33 was 
made at a time when insight into the in vivo metabolism of 
NO and its diversity of actions at the subcellular level was 
limited. Moreover, NO2Tyr was also detected in synovial 
ﬂuid in patients with rheumatoid arthritis34 and its presence 
is considered a hallmark of oxidative damage even today. 
NO2Tyr will remain indicative of nitration reactions and may 
give rise to neoepitope and auto-antibody formation in joint 
synovial ﬂuid,35 but researchers can no longer be so sure 
about its origin and function.36
Experimentally induced OA tends to differ substantially 
from the human form and mechanisms vary between animal 
models depending on insult, age and species.37 Even the 
use of NOS knockout animals has its limitations since the 
lack of one NOS isoform can lead to compensatory upregu-
lation of one of the other isoforms, which may explain some 
of the controversy regarding the role of iNOS in OA.38,39
Later studies linked NO production to chondrocyte apop-
tosis and inhibition of matrix synthesis, but revealed con-
ﬂicting results concerning the role of NO.40,41 The ﬁnding 
that NO-mediated cell death requires the generation of 
additional ROS42,43 points to a cross-talk between NO and 
ROS signaling. While these studies clearly demonstrate 
an involvement of NO in OA and the differential effects of 
ROS and NO produced by different NOS isoforms in joint 
inﬂammation are increasingly appreciated,44 these associa-
tions do not establish a cause/effect relationship. Thus, the 
question as to whether NO is of beneﬁt or detriment in OA45
remains open.
A closer look at the methods section of some papers and 
the context in which the results are discussed often reveals 
erroneous assumptions and misconceptions about the bio-
chemistry (to the extent that NO is at times confused with 
ROS), questioning the validity of at least some of the con-
clusions drawn. Given the central role NO plays in many 
cell regulatory processes it is of obvious importance to 
deﬁne whether NO is “good” or “bad”, whether there is “too 
much” or “not enough”, and at what stage of the disease 
the patient is most likely to beneﬁt from a pharmacologi-
cal intervention if NO was the target. This would seem to 
be especially important for OA because of the current lack 
of true disease-modifying drugs, validated biomarkers and 
other diagnostic tools and the knowledge gap concerning 
disease mechanism and pathogenesis, in particular as 
to the relative contribution of bone, synovium, cartilage, 
inﬂammatory cells and T-cells because NO is involved in 
the functional regulation of each one of these cell types at 
multiple levels.
Too much or not enough NO in osteoarthritis 
and does it really matter?
Although the correct answer to the above question has an 
obvious impact on treatment options and choice of pharma-
cological intervention, it is unlikely that the absolute amounts 
of NO produced will tell us much about the direction in which 
the disease is progressing. Without understanding the rela-
tive contribution of local versus systemic factors, knowing 
what the concentration of nitrite/nitrate is in synovial ﬂuid 
or blood is of limited value. We will need to know how much 
is produced over time in what particular cell/joint compart-
ment and what effect it has on individual signaling pathways 
to make sense of this information. Currently available tools 
are too crude to address these issues. In addition to spatial 
and quantitative information about NO production we need 
to know in what form it arrives at its biological target(s). This 
requires better knowledge about the microenvironmental 
conditions, e.g. the redox poise in different compartments, 
as this has a major impact on the fate of NO. If NO as such 
is required to trigger a speciﬁc response and this pathway 
is important for cell integrity and proper joint function, any 
factor or event that has the potential to increase local ROS 
production will reduce the concentration of NO available for 
interaction with its biological target. The magnitude of the 
problem should encourage industry, academia and fund-
ing bodies alike to invest in the development of methodol-
ogy capable of monitoring origin and fate of NO to obtain a 
“higher resolution picture of NO biochemistry” in complex 
biological systems such as the joint.
The ability to address the role of NO in OA is also ham-
pered by the lack of a straightforward functional assay to 
assess NO availability in the joint. In the cardiovascular 
ﬁeld impaired NO availability translates into readily mea-
surable changes in vascular reactivity. Those changes can 
be assessed non-invasively by quantifying the increase in 
forearm blood ﬂow in response to a brief period of ischemia 
using venous occlusion plethysmography or Doppler tech-
niques. If the endothelium is intact and healthy (and NO 
availability adequate), a brief occlusion of arterial inﬂow 
results in blood vessel dilatation. Atherosclerosis, hyperten-
sion, obesity and other diseases known to be associated 
with enhanced oxidative stress are characterized by endo-
thelial dysfunction, which presents as impaired dilatation or 
even vasoconstriction. Redox status and superoxide pro-
duction are the major determinants of NO availability in the 
vasculature46,47 and elsewhere. Thus, without any additional 
biochemical measurement this relatively simple functional 
test of systemic vascular reactivity allows identiﬁcation 
of patients at risk for vascular complications in cardio-
metabolic disorders, and the forearm vasculature is often 
Osteoarthritis and Cartilage S7
used as a proxy for NO formation in other vascular beds.48
Although there are indications for a link between endothe-
lial dysfunction and OA,49 which together with increased cir-
culating nitrite/nitrate levels would suggest involvement of 
a systemic inﬂammatory component, there has been little 
research on the subject to date.
Relatively little is known about the cell types and tissues 
that produce NO under physiological conditions in the joint 
and what particular isoforms are involved.3 The latter may 
be important because ﬁne-regulation by post-translational 
modiﬁcation, cofactor requirements and speciﬁc activities 
differ between isoforms. Moreover, NO production is not 
only determined by the expression of speciﬁc NOS iso-
forms and local substrate/cofactor availabilities but, also by 
their interaction with other proteins. Nothing is known about 
changes in NOS trafﬁcking and translocation processes in 
the different cell types that make up a functional joint.
Chemical biology of NO – the bare essentials
The realization that the chemistry of NO is a major determi-
nant of the outcome of its interaction with biological targets 
has been crucial for understanding why the same molecule 
can be protective/regulatory under one condition and del-
eterious/cytotoxic under another. Wink and colleagues have 
been instrumental in developing a framework according to 
which the chemical biology of NO is divided into direct and 
indirect effects (see Figure 2; for a more comprehensive 
treatment of this subject see Refs. 50–52). Brieﬂy, direct 
effects are those mediated by NO itself and include the 
interaction with metals and metalloproteins as well as the 
scavenging of other free radicals. Examples of the former 
would be the binding of NO to the heme group of e.g., solu-
ble guanylyl cyclase, cytochrome P-450, cytochrome c oxi-
dase, cyclooxygenase, peroxidases and others metallopro-
teins; examples of the latter are exempliﬁed by the trapping 
of superoxide (forming peroxynitrite) and hydroxyl radicals 
(forming nitrous acid), lipid peroxides (a chain-breaking 
event that prevents lipid peroxidation) and other free radi-
cals, reactions that contribute to the antioxidative effects of 
NO.53 Direct effects dominate at low NO ﬂuxes and prob-
ably account for a signiﬁcant part of its regulatory effects in 
physiology. Under conditions of enhanced oxidative stress 
and higher rates of NO production the likelihood of interac-
tion with oxygen and ROS increases, leading to enhanced 
formation of reactive nitrogen oxide species (RNOS; also 
called ‘reactive nitrogen species’; these include ONOO–,
NO2, N2O3 and other species). These secondary reaction 
products of NO are responsible for the so-called ‘indirect 
effects of NO’ and lead to nitrosation, oxidation, and nitration 
of biomolecules, chemistries NO itself does not entertain. 
The nature of the reaction products is dictated by the avail-
ability of target molecules in the vicinity of the RNOS and 
the prevalence of other competing and scavenging mech-
anisms. In a biological environment, a complex mixture of 
low-molecular weight compounds and post-translational 
protein modiﬁcations is expected to occur near ‘hotspots’ of 
RNOS formation. While some of the reaction products are 
stationary (e.g. nitrated tyrosine residues of proteins) and 
only become detectable in free form in the circulation fol-
lowing proteolysis, others (e.g. S-nitrosoalbumin) can travel 
signiﬁcant distances to reach targets remote from the site 
of the actual nitrosative event. The half-lifes of NO-related 
metabolites vary substantially (from seconds to hours), 
depending on the chemical nature of the product and the 
availability of other cell constituents (e.g. reduced thiols, 
ascorbate, metals) triggering their degradation. This sce-
nario helps understanding why predictions about the in vivo
fate of NO are difﬁcult to make and illustrates the complexity 
of NO metabolism from the angle of its production. Regret-
tably, the situation does not get much easier when it comes 
to NO breakdown. Contrary to the major inactivation mecha-
nism for NO in blood, the conversion to nitrate by oxyhemo-
globin in red blood cells (see Figure 1), the fate of NO in 
other cells and tissues is less well characterized. The reac-
tion of NO with oxygen, yielding largely nitrite, is rather slow 
compared with other competing mechanisms and unlikely 
to play a signiﬁcant role in regulating local NO availability. 
Mitochondrial consumption processes may occur via direct 
oxidation at the level of complex IV54 or by reaction with ROS 
and may be involved in the regulation or ﬁne-tuning of mito-
chondrial activity by NO. The latter is a crucial element of 
NO biology55 and mitochondrial respiratory activity is altered 
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in OA.56 ATP depletion leads to spontaneous knee OA in 
guinea pigs57 and mitochondrial dysfunction is thought to be 
involved in OA.58,59 While several reports have discussed the 
role of NO in modulating mitochondrial activity in the context 
of chondrocyte metabolism and matrix production,60,61 this 
promising ﬁeld seems to be in its infancy. 
Oxidative stress and the role of NO as a cellular 
antioxidant
It has become increasingly clear over the years that “oxi-
dative stress” is not simply an inevitable consequence 
of aerobic life and the formation of ROS (including O2•–,
•OH, and H2O2 among others) an unwanted side-effect, but 
that distinct ROS are purposefully generated to fulﬁll cell 
signaling and redox-regulatory functions.62,63 ROS forma-
tion is increased in inﬂammation, and enhanced oxidative 
damage has been linked to OA and cartilage destruction. 
Oxidative stress markers are typically increased and antiox-
idant concentrations reduced in this setting.64–66 There are 
a number of interesting parallels between ROS and NO for-
mation and the “friend or foe” question surfaces more than 
once in the OA/ROS literature.67 Of note, the low oxygen 
tension in the joint favors oxidative stress already under 
physiological conditions since ROS production is paradoxi-
cally enhanced in hypoxia.68
There are numerous sources of ROS within the cell includ-
ing components of the mitochondrial respiratory chain, 
cytochrome P-450, xanthine oxidoreductase, NADPH oxi-
dase and others. Superoxide, a major determinant of NO 
availability in the vasculature, has also been shown to limit 
NO signaling.69 The classical deﬁnition of oxidative stress 
envisioned an imbalance between oxidant production 
and antioxidant capacity,70 with free metals (iron, copper) 
determining the likelihood of hydroxyl radical formation and 
oxidative damage. The reaction of NO with superoxide is 
extremely fast, outcompeting the fastest enzymatic process 
currently known, that of superoxide dismutation. Oxidative 
stress may therefore be better understood as an imbalance 
in NO/superoxide availability with a shift towards a per-
oxynitrite/nitrogen dioxide (NO2) dominated chemistry. This 
situation is synonymous with a state of low NO availability,71
suggesting that associated perturbations of cell function 
under these conditions might beneﬁt from an enhanced NO 
availability, provided those processes are still reversible.
NO availability can be increased by several means: i) 
scavenging of superoxide by either local injection of super-
oxide dismutase (SOD) – a therapeutic approach with 
limited effectiveness in OA – SOD overexpression or appli-
cation of SOD mimetics; ii) enhancement of NOS substrate 
(L-arginine) or cofactor (tetrahydrobiopterin) availability; iii) 
inhalation of NO gas; and iv) application of NO donors.b
Conceivably, nitrite may also be able to serve as a source 
of NO under hypoxic conditions (see above). 
NO can abate the oxidative chemistry mediated by ROS, 
reduce lipid peroxidation and protect cells from metal and 
peroxide-induced oxidative damage.73 Moreover, NO spares 
Į-tocopherol and other antioxidants from oxidation,74 a pro-
cess shown to prevent cartilage matrix protein degrada-
tion.75 In fact, NO is a key mechanism that limits oxidative 
injury to mammalian cells53 and surprisingly small concen-
trations are required to effectively inhibit lipid peroxidation.76
In addition to these antioxidative actions, NO has potent 
anti-inﬂammatory effects by down-regulation of the activity 
of activated neutrophils and macrophages, preventing neu-
trophil adhesion and modulating T-cell function.77 Moreover, 
it modulates both production and release of pro-inﬂamma-
tory cytokines and the activity of transcription factors such 
as NF-ɤB, a master-regulator of the inﬂammatory signal-
ing cascade. Its effects on prostaglandin production are 
more difﬁcult to assess given the complexity of the cross-
talk between NOS and cyclooxygenase expression and 
activities.78 Another potential anti-inﬂammatory mechanism 
transduced by NO is via nitration of unsaturated fatty acids 
(including prostaglandins) and the action of these reaction 
products on PPAR-Ȗ receptors.79
Taken together, NO has potent antioxidative and anti-
inﬂammatory effects. As much as the reciprocal regulation 
of ROS and NO offers opportunities for ﬁne-regulation of a 
multitude of cell biological processes, it appears to become 
a source of concern when the balance shifts from an NO-
dominated to a superoxide-dominated chemistry. Can this 
happen by mechanisms other than a reduced antioxidant 
availability or increases in ROS production? The following 
section will address the cellular NO-generating machinery.
Peroxynitrite, nitrotyrosine and NOS uncoupling
While peroxynitrite is a powerful oxidant and nitrating agent 
endowed with apoptosis-inducing, cytotoxic and pro-inﬂam-
matory effects, its formation is strictly limited to sites of 
almost equimolar ﬂuxes of NO and superoxide.80 This pecu-
liar behavior implies that peroxynitrite formation (and con-
secutive oxidation/nitration chemistry) is less than that at a 
roughly 1:1 molar ratio of NO and O2– whenever NO pro-
duction exceeds superoxide formation or vice versa. This 
would restrict NO2Tyr formation to sites with comparable 
NO/O2– production rates, if it were not for another mecha-
nism of nitration in cells.
Recent results suggest that a signiﬁcant portion, if not the 
majority of NO2Tyr originates from peroxidases/H2O2-medi-
ated oxidation of nitrite to nitrogen dioxide (NO2) rather than 
from peroxynitrite.81 With the ubiquitous availability of nitrite 
and H2O2 (concentrations of which are increased in inﬂam-
mation) peroxynitrite formation would seem to be no longer 
spatially limited to the sites of concomitant NO/O2– forma-
tion but rather dependent on the expression of peroxidases, 
which are abundant in inﬂammatory cells. While this may 
enlarge the activity radius of nitrative and oxidative chem-
istry and contribute to more widespread protein nitration, 
the consequences for enzymatic NO production from NOS 
are serious.
NOS requires several cofactors for NO generation, includ-
ing oxygen, NADPH and tetrahydrobiopterin. The latter is 
required for the transfer of electrons from NADPH to its 
heme center, where L-arginine is oxidized to L-citrulline and 
NO. Increased oxidative stress (from whatever source) with 
enhanced formation of peroxynitrite and/or NO2 formation 
from nitrite, leads to enhanced oxidation reactions. If this 
situation persists beyond the window of protection afforded 
by the endogenous antioxidant system the NO produc-
ing machinery itself can become a target of ROS/RNOS 
action. As tetrahydrobiopterin becomes gradually oxidized 
oxygen reduction uncouples from NO synthesis and trans-
forms NOS into a superoxide-producing pro-inﬂammatory 
bOf note, there are many types of NO donors used in experimental 
studies which may generate/donate nitrosonium (NO+), nitroxyl 
(NO-/HNO), peroxynitrite or cyanide instead of or in addition to 
the desired NO, complicating the interpretation of results and 
the assessment of what part of the effect was actually due to NO 
itself.72
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enzyme.82 Thus, not only is NOS no longer capable of gen-
erating NO, it now contributes to the perpetuation of oxida-
tive stress itself. Given the large amounts of iNOS expressed 
in inﬂammation, the additional oxidative stress generated 
via this mechanism may be signiﬁcant. No further enhance-
ment of NOS expression or arginine availability will help 
correcting this situation; only local ROS scavenging (e.g., 
by application of combined SOD/catalase mimetics) or an 
increase in NO availability (e.g., NO donors) can abate this 
chemistry and stop the vicious cycle.
The NO/ROS balance and its significance for 
cellular redox signaling and hypoxia-induced 
gene expression
ROS and NO are generated by a multitude of mechanisms 
under physiological conditions and the production of both 
is enhanced in inﬂammation. Global and local changes in 
ROS production and redox poise have a major impact on 
NO metabolism and the balance between oxidative, nitrative 
and nitrosative chemistries (Figure 3), with vast differences 
in expression and activity of multiple enzymes despite little 
or no changes in overall NO production. Since both the NO 
source (L-arginine versus nitrite) and mechanisms of con-
sumption (trapping by oxyhemoglobin or superoxide versus 
consumption by cytochrome c oxidase) may change as 
oxygen concentrations vary, the situation is complex and 
dynamic. What kind of metabolites are formed when and 
where will depend on the i) rates of formation of NO and O2–;
ii) NO and ROS scavenging mechanisms; iii) local oxygen 
and carbon dioxide concentrations; iv) microenvironmental 
redox poise; v) chemical nature of the biological target; and 
– like in real estate – vi) location, location, location.
Since the pathways of NO and ROS generation are inti-
mately connected it would seem that their contribution to OA 
cannot be studied in isolation. The particular situation of the 
joint places an emphasis on the availability of oxygen28 and 
carbon dioxide83 for modulation of the downstream chemis-
try of concomitant NO and ROS formation. The associated 
redox changes further suggest an involvement of speciﬁc 
hypoxic signalling events. Where does all this lead us to and 
what are the likely molecular targets?
The interaction of thiols with metals has shaped evolu-
tionary biochemistry for eons.84 Many mammalian proteins 
contain one or more sulfhydryl (SH) groups that render their 
activity subject to redox regulation. Thiols are “nanotrans-
ducers of redox chemistry” that deﬁne which ROS and 
RNOS acts as second messenger and in what direction.85,86
Thiols present in various transcription factors, such as 
NFɤB, AP-1, and p53 and transcription factors with antioxi-
dative-response-element binding sites such as Nrf2 act as 
redox sensors and transcriptionally control the regulation 
of genes critical for cell homeostasis and redox status. It 
appears reasonable, therefore, to assume that the NO/ROS 
balance plays a crucial role in the development and pro-
gression of OA by virtue of its effects on redox signalling 
pathways. 
The shift in redox poise towards more oxidation will not 
only affect general antioxidant status but also cause ascor-
bate depletion. This may have important implications for 
hypoxic signalling via hypoxia-inducible factor-Į (HIF-1Į)
and matrix production. Besides its classical antioxidant 
function ascorbate serves as a cofactor for prolyl hydrox-
ylases, enzymes important in the regulation of HIF-1Į
degradation and collagen production. Impairment of HIF-
1Į hydroxylation due to ascorbate deﬁciency would spare 
this transcription factor from ubiquitination and proteasomal 
Fig. 3. Oxidative, Nitrative and Nitrasative Stress and Their Relationship to Cell Signaling? – A Balancing Act. Abbr.: COX = cyclooxygenase, 
Cyt C ox = cytochrome c oxidase, H2O2 = hydrogen peroxide, HbO2 = oxyhemoglobin, LOO • = lipid peroxyl radical, NO = nitric oxide, NO2Tyr =
nitrotyrosine, NO2 = nitrogen dioxide, N2O3 = dinitrogen trioxide, NO2– = nitrite, NO3– = nitrate, O2 = oxygen, O2– = superoxide, •OH = hydroxyl 
radical, ONOO– = peroxynitrite, P450 = cytochrome P450, sGC = soluble guanylyl cyclase, SH = thiol, SSR = mixed disulﬁde, SOxH = oxidized 
thiol (sulfenic, sulﬁnic, sulfonic acids), SNO = nitrosothiol, RX = biomolecule, RXNO2 = nitrated biomolecule.
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degradation (its fate under normoxic conditions), leading 
to accumulation and “superinduction” of hypoxia-induced 
gene expression. In addition, redox changes are likely to 
affect HIF expression and activity in an ascorbate-indepen-
dent manner. Together, these changes may induce local 
alteration in glycolysis, pH and energy regulation, apoptosis 
and other metabolic processes incompatible with the situ-
ation at hand and potentially detrimental for cell survival if 
uncoupled from other oxygen-dependent processes. The 
above scenario is consistent with the effectiveness of gold 
compounds and penicillamine in rheumatic disease;87 the 
disappointing clinical results with ascorbate and other anti-
oxidants in OA despite the fact that ascorbate deﬁciency 
in animal models is associated with ER stress and OA-like 
symptoms;88,89 effects of ascorbate on cartilage metabolism 
and matrix production;90 distinct threshold concentrations of 
NO regulating HIF-1Į accumulation;91 altered mitochondrial 
respiratory activity56 and increased HIF-1Į in osteoarthritic 
articular chondrocytes;92 and peroxynitrite-mediated mito-
chondrial dysfunction with caspase-independent chondro-
cyte apoptosis.93
If some of the current investments in the search for pos-
sible genomic underpinnings of the disease would be used 
for integrative, systems-wide approaches using a combina-
tion of ‘omics’ techniques instead we might arrive earlier at 
the conclusion that there is nothing wrong with the genes in 
OA, but rather with the way their expression is regulated by 
NO and ROS. Insight into these processes might increase 
our chances for the development of true disease modify-
ing drugs and preventive approaches to tackle this crippling 
disease.
Conclusions
NO is a pleiotropic signalling and effector molecule with 
a surprisingly rich chemistry, and many of its secondary 
metabolites (including nitroso and nitrosyl species as well as 
nitrite) have potent biological activities in their own right. The 
fate of NO in vivo is complex and differs profoundly between 
physiology and pathology. It is likely that local NO availabil-
ity is impaired under inﬂammatory conditions, despite mas-
sive upregulation of NO production by iNOS in attempts 
to compensate for the accelerated breakdown secondary 
to increased oxidative stress. This creates a vicious cycle 
that leads to NOS uncoupling, further compromising NO 
availability. These changes lead to progressive nitrosation, 
nitration and oxidation of other proteins and biomolecules, 
exacerbating the shift in NO/ROS balance and the changes 
in downstream redox signalling and gene expression. Thus, 
the presence of increased concentrations of nitrosation and 
nitration products in the joint is not necessarily an indication 
for too much NO, but rather indicative of oxidative stress 
with consecutive alterations in NO metabolism. Nitrite and 
exogenous NO may conceivably protect tissues from the 
deleterious consequences of NOS uncoupling by virtue of 
its antioxidative and anti-inﬂammatory effects – a rescue 
mechanism that is independent of the classical cardiovas-
cular effects of NO aimed at restoring normal physiological 
function. Given the prominent role NO plays in OA, modu-
lation of NO availability and cellular NO/ROS-dependent 
redox poise appear to be attractive targets for future phar-
macological intervention, but further research efforts are 
required to assess whether endogenous NO production 
needs to be inhibited or local NO concentrations enhanced 
and whether NO availability can be modulated differentially 
in different cell types. 
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